Total Payments
$70,215
2024 Payments
$12,494
Companies
56
Transactions
730
Medicare Patients
2,354
Medicare Billing
$1.2M
Payment Breakdown by Category
Consulting$34,585 (49.3%)
Other$16,625 (23.7%)
Food & Beverage$15,348 (21.9%)
Travel$3,327 (4.7%)
Education$329.57 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $34,585 | 16 | 49.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,625 | 11 | 23.7% |
| Food and Beverage | $15,348 | 683 | 21.9% |
| Travel and Lodging | $3,327 | 12 | 4.7% |
| Education | $329.57 | 8 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $19,504 | 95 | $0 (2024) |
| Biogen, Inc. | $16,356 | 49 | $0 (2024) |
| Genentech USA, Inc. | $13,518 | 59 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $6,294 | 90 | $0 (2024) |
| GENZYME CORPORATION | $5,448 | 32 | $0 (2023) |
| TG Therapeutics, Inc. | $1,538 | 28 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $1,046 | 31 | $0 (2024) |
| Celgene Corporation | $700.13 | 64 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $572.01 | 33 | $0 (2024) |
| ABBVIE INC. | $481.61 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,494 | 281 | Genentech USA, Inc. ($3,621) |
| 2023 | $3,082 | 147 | EMD Serono, Inc. ($340.49) |
| 2022 | $13,900 | 138 | Genentech USA, Inc. ($7,800) |
| 2021 | $5,621 | 44 | GENZYME CORPORATION ($2,170) |
| 2020 | $20,401 | 37 | Biogen, Inc. ($14,393) |
| 2019 | $13,294 | 79 | EMD Serono, Inc. ($7,084) |
| 2018 | $1,424 | 4 | Biogen, Inc. ($1,205) |
All Payment Transactions
730 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $80.68 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Neurology | ||||||
| 12/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Central Nervous System | ||||||
| 12/16/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $32.58 | General |
| Category: Immune | ||||||
| 12/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $28.51 | General |
| Category: Rare Disease | ||||||
| 12/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.13 | General |
| 12/13/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Musculoskeletal | ||||||
| 12/11/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.47 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: PAIN | ||||||
| 12/10/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $202.31 | General |
| 12/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $90.00 | General |
| 12/10/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Neuroscience | ||||||
| 12/09/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $27.12 | General |
| Category: Neurology | ||||||
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| 12/06/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.01 | General |
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: PAIN | ||||||
| 12/03/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 581 | 24,891 | $1.8M | $560,822 |
| 2022 | 12 | 686 | 6,934 | $370,975 | $71,039 |
| 2021 | 10 | 563 | 15,433 | $640,727 | $221,134 |
| 2020 | 13 | 524 | 20,050 | $892,307 | $342,768 |
Total Patients
2,354
Total Services
67,308
Medicare Billing
$1.2M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 13 | 9,300 | $1.0M | $275,110 | 26.9% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 17 | 8,700 | $304,500 | $165,270 | 54.3% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 13 | 1,970 | $177,300 | $75,288 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 149 | $32,780 | $11,549 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 65 | 83 | $24,900 | $7,075 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $19,760 | $6,201 | 31.4% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 40 | 40 | $89,400 | $5,994 | 6.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 51 | $26,010 | $4,111 | 15.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 44 | 58 | $13,224 | $2,708 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $11,704 | $2,455 | 21.0% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 44 | 4,200 | $6,300 | $1,103 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 18 | $2,700 | $1,083 | 40.1% |
| 72142 | Mri scan of upper spinal canal with contrast | Office | 2023 | 14 | 14 | $24,444 | $1,063 | 4.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 36 | $5,976 | $560.54 | 9.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 20 | 122 | $1,830 | $502.54 | 27.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 21 | $3,486 | $381.13 | 10.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 18 | 33 | $3,300 | $367.24 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 213 | 280 | $61,600 | $22,343 | 36.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 102 | 124 | $37,200 | $14,421 | 38.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 83 | 83 | $31,540 | $9,426 | 29.9% |
| 70553 | Mri scan of brain before and after contrast | Office | 2022 | 61 | 61 | $136,335 | $9,404 | 6.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 57 | 57 | $15,162 | $3,929 | 25.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 26 | 36 | $18,360 | $3,237 | 17.6% |
| 72142 | Mri scan of upper spinal canal with contrast | Office | 2022 | 27 | 27 | $47,142 | $2,051 | 4.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $4,235 | $1,706 | 40.3% |
About Dr. Casey Jeffreys, M.D
Dr. Casey Jeffreys, M.D is a Neurology healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2014. The National Provider Identifier (NPI) number assigned to this provider is 1619395092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Casey Jeffreys, M.D has received a total of $70,215 in payments from pharmaceutical and medical device companies, with $12,494 received in 2024. These payments were reported across 730 transactions from 56 companies. The most common payment nature is "Consulting Fee" ($34,585).
As a Medicare-enrolled provider, Jeffreys has provided services to 2,354 Medicare beneficiaries, totaling 67,308 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Raleigh, NC
- Active Since 04/02/2014
- Last Updated 04/01/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1619395092
Products in Payments
- Mavenclad (Drug) $8,671
- TYSABRI (Biological) $8,520
- OCREVUS (Biological) $7,926
- Mavenclad (Biological) $6,951
- VUMERITY (Drug) $5,833
- MAYZENT (Drug) $4,547
- Ocrevus (Biological) $3,664
- AUBAGIO (Drug) $2,923
- TECFIDERA (Drug) $1,800
- Enspryng (Biological) $1,763
- BRIUMVI (Drug) $1,538
- KESIMPTA (Drug) $1,058
- ZEPOSIA (Drug) $698.03
- ULTOMIRIS (Biological) $666.82
- ACTHAR (Biological) $588.67
- MAVENCLAD (Drug) $340.49
- NURTEC ODT (Drug) $296.70
- BAFIERTAM (Drug) $267.97
- Briviact (Drug) $259.22
- Hizentra (Biological) $248.02
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Raleigh
John Scagnelli, M.d, M.D
Neurology — Payments: $434,945
Neurology $434,945
Dr. Tibor Becske, M.d, M.D
Neurology — Payments: $387,165
Neurology $387,165
Dr. Keith Hull, M.d, M.D
Neurology — Payments: $140,830
Neurology $140,830
John Collins, M.d, M.D
Neurology — Payments: $25,595
Neurology $25,595
Dr. Kenneth Carnes, M.d, M.D
Neurology — Payments: $23,277
Neurology $23,277
Dr. William Ferrell, M.d, M.D
Neurology — Payments: $23,271
Neurology $23,271